Sonnet Biotherapeutics

SONN

US83548R4020

Delayed Nasdaq Other stock markets 21:00:00 02/12/2025 GMT			5-day change	1st Jan Change
1.260 ^USD	-59.35%		-.--%	-

12-16	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-02	Top Midday Decliners	MT

Top Midday Decliners

Published on 12/02/2025 at 07:26 pm GMT

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Sonnet Biotherapeutics

12-16	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-02	Top Midday Decliners	MT
12-02	Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies	RE
12-01	Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index	CI
12-01	Hyperliquid Strategies Inc completed the acquisition of Sonnet BioTherapeutics Holdings, Inc. in a reverse merger transaction.	CI
15/10/25	Sonnet BioTherapeutics Holdings, Inc. Collaborates with Spanishos on Non-Clinical Study Using New Alternate Methodologies Based Patient-Derived Tumoroid Platform	CI
15/09/25	Top Premarket Decliners	MT
13/08/25	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
11/08/25	Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer	CI
04/08/25	Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study	MT
04/08/25	Sonnet Biotherapeutics expands trial of SON-1010 with atezolizumab in advanced ovarian cancer	RE
04/08/25	Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	CI
15/07/25	Top Premarket Decliners	MT
14/07/25	Top Midday Gainers	MT
14/07/25	Traders Digest Tariff Announcements, Driving Premarket Losses for US Equity Futures	MT

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Employees

Sector

More about the company